Movement Alert｜Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised

Market Focus

Yesterday

On October 7, Glaukos rose 6.57% in regular trading, trading at $172.205 per share, with turnover of $30.178 million. The move follows the company's significant upward revision to its 2026 sales guidance.

The company now expects 2026 net sales of $680 million to $700 million, sharply above the FactSet consensus estimate of $630 million. This upward revision comes after Glaukos reported second quarter adjusted loss per share of $(0.14), beating consensus estimates of $(0.22), with revenue of $185.61 million exceeding the anticipated $150.98 million.

Prior to this, Glaukos had already raised its 2026 sales outlook to $620 million to $635 million from $600 million to $620 million in late April, indicating accelerating commercial momentum across its ophthalmic pharmaceutical and medical technology portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1188555533"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188555533\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188555533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-07 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188555533","market":"us","top_or_hot":-1,"title":"Movement Alert｜Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised","media":"Market Focus","content":"<p><p>On October 7, Glaukos rose 6.57% in regular trading, trading at $172.205 per share, with turnover of $30.178 million. The move follows the company's significant upward revision to its 2026 sales guidance.</p><p>The company now expects 2026 net sales of $680 million to $700 million, sharply above the FactSet consensus estimate of $630 million. This upward revision comes after Glaukos reported second quarter adjusted loss per share of $(0.14), beating consensus estimates of $(0.22), with revenue of $185.61 million exceeding the anticipated $150.98 million.</p><p>Prior to this, Glaukos had already raised its 2026 sales outlook to $620 million to $635 million from $600 million to $620 million in late April, indicating accelerating commercial momentum across its ophthalmic pharmaceutical and medical technology portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-07 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 7, Glaukos rose 6.57% in regular trading, trading at $172.205 per share, with turnover of $30.178 million. The move follows the company's significant upward revision to its 2026 sales guidance.</p><p>The company now expects 2026 net sales of $680 million to $700 million, sharply above the FactSet consensus estimate of $630 million. This upward revision comes after Glaukos reported second quarter adjusted loss per share of $(0.14), beating consensus estimates of $(0.22), with revenue of $185.61 million exceeding the anticipated $150.98 million.</p><p>Prior to this, Glaukos had already raised its 2026 sales outlook to $620 million to $635 million from $600 million to $620 million in late April, indicating accelerating commercial momentum across its ophthalmic pharmaceutical and medical technology portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1188555533","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188555533","pubTimestamp":1791381339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 7, Glaukos rose 6.57% in regular trading, trading at $172.205 per share, with turnover of $30.178 million. The move follows the company's significant upward revision to its 2026 sales...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"走势警报|Glaukos 常规交易上涨 6.57%，2026 年销售指引大幅上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"On October 7, Glaukos rose 6.57% in regular trading, trading at $172.205 per share, with turnover of $30.178 million. The move follows the company's significant upward revision to its 2026 sales guidance.The company now expects 2026 net sales of $680 million to $700 million, sharply above the FactSet consensus estimate of $630 million. This upward revision comes after Glaukos reported second quarter adjusted loss per share of $(0.14), beating consensus estimates of $(0.22), with revenue of $185.61 million exceeding the anticipated $150.98 million.Prior to this, Glaukos had already raised its 2026 sales outlook to $620 million to $635 million from $600 million to $620 million in late April, indicating accelerating commercial momentum across its ophthalmic pharmaceutical and medical technology portfolio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}